Omeros closes $68.3 million public stock offering

11:00 EDT 23 Aug 2017 | Healio

Omeros has closed its underwritten public offering with 3 million shares of its common stock being sold at $22.75 per share, according to a company press release.The company generated $63.6 million of net proceeds from the offering, which it intends to use for “general corporate purposes.” This includes research and development of its OMS721 programs, clinical trials, manufacturing costs and other costs that will assist the company in advancing its product candidates toward biologic license application and new drug application submissions.

Original Article: Omeros closes $68.3 million public stock offering


More From BioPortfolio on "Omeros closes $68.3 million public stock offering"

Quick Search


Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...